Disease · MONDO_0005416
osteoarthritis, knee
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. osteoarthritis, knee. Diseases, record MONDO_0005416. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005416
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Knee Osteoarthritides, Knee Osteoarthritis, Knee, Osteoarthritis Of, Knees, Osteoarthritis Of, Osteoarthritides, Knee, Osteoarthritis Of Knee, Osteoarthritis Of Knees, osteoarthritis of the knee
- Open Targets
Drugs143
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUMIRACOXIB | CHEMBL404108 | Small molecule | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| HYALURONIC ACID | CHEMBL5314376 | Phase 3 | ClinicalTrials.gov | 31 | 31 | 29 | Drugs and targets | |
| CELECOXIB | CHEMBL118 | Small molecule | Phase 3 | ClinicalTrials.gov | 19 | 19 | 19 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 9 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| TRIAMCINOLONE | CHEMBL1451 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 4 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 4 | Drugs and targets |
| DICLOFENAC SODIUM | CHEMBL1034 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 10 | 9 | 9 | Drugs and targets |
| GLUCOSAMINE SULFATE | CHEMBL3989750 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| NAPROXEN | CHEMBL154 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
1 to 10 of 143
See all 143 drugsTargets175
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PTGS2 | Cyclooxygenase | 15 | Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor | Approval | https://conductscience.org/library/genes/5743 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 14 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 8 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| OPRM1 | Mu-type opioid receptor | 7 | Mu opioid receptor agonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 6 | Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| NGF | Beta-nerve growth factor | 4 | Beta-nerve growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/4803 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 4 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
1 to 10 of 175
See all 175 targetsTrials238
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 13 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02683239 | Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip | Phase 3 | 5,331 | 2023-10-13 | Osteoarthritis of the Knee or Hip | FASINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00565812 | A Long-Term, Placebo-Controlled X-Ray Study Investigating the Safety and Efficacy of SD-6010 in Subjects With Osteoarthritis of the Knee | Phase 2 | 1,457 | 2016-12-30 | Osteoarthritis | CINDUNISTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03988023 | Study of Ampion for the Treatment of Pain and Function in Patients With Severe Osteoarthritis of the Knee. | Phase 3 | 1,043 | 2022-10-05 | Severe Osteoarthritis of the Knee | ASPARTYL-ALANYL-DIKETOPIPERAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT00421928 | Tapentadol (CG5503) | Phase 3 | 1,030 | 2010-04-23 | Osteoarthritis, Knee, Pain | OXYCODONE, TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
| NCT00704847 | Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study) | Phase 3 | 1,030 | 2012-09-12 | Osteoarthritis | CALCITONIN, SMC021 | Its record names the disease | ClinicalTrials.gov |
| NCT02913521 | Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1% | Phase 3 | 934 | 2021-02-26 | Osteoarthritis, Knee | DICLOFENAC SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT00733902 | Tanezumab in Osteoarthritis of the Knee | Phase 3 | 697 | 2021-03-22 | Arthritis, Osteoarthritis | TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00664560 | Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis | Phase 3 | 614 | 2012-02-27 | Osteoarthritis | CELECOXIB, NAPROXEN | Its record names the disease | ClinicalTrials.gov |
| NCT01919164 | A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee | Phase 2 | 549 | 2020-07-13 | Osteoarthritis, Knee | SPRIFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01799213 | Discontinuing NSAIDs in Veterans With Knee Osteoarthritis | Phase 2 | 490 | 2019-12-16 | Knee Osteoarthritis | MELOXICAM | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 238
See all 238 trialsComparisons in its trials36
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ampion 4 mL Dose vs Placebo 4 mL Dose: deaths from any cause | 1 of 520 | 0 of 523 | 1,043 | NCT03988023 | Trial comparisons |
| Ampion 4 mL Dose vs Placebo 4 mL Dose: serious adverse events | 16 of 520 | 11 of 523 | 1,043 | NCT03988023 | Trial comparisons |
| SMC021 Oral Calcitonin vs SMC021 Placebo: serious adverse events | 77 of 520 | 80 of 508 | 1,028 | NCT00704847 | Trial comparisons |
| 4 mL AMPION™ vs 4 mL Saline Placebo: deaths from any cause | 0 of 236 | 0 of 243 | 479 | NCT02556710 | Trial comparisons |
| 4 mL AMPION™ vs 4 mL Saline Placebo: serious adverse events | 2 of 236 | 4 of 243 | 479 | NCT02556710 | Trial comparisons |
| Tramadol HCl Contramid® Once A Day vs Tramadol HCl Twice a Day (SR): serious adverse events | 3 of 215 | 8 of 215 | 430 | NCT00950651 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: deaths from any cause | 0 of 269 | 0 of 135 | 404 | NCT05064735 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: serious adverse events | 27 of 269 | 11 of 135 | 404 | NCT05064735 | Trial comparisons |
| Diacerein vs Celecoxib: deaths from any cause | 0 of 186 | 0 of 190 | 376 | NCT02688400 | Trial comparisons |
| Diacerein vs Celecoxib: serious adverse events | 3 of 186 | 4 of 190 | 376 | NCT02688400 | Trial comparisons |
1 to 10 of 36
See all 36 comparisons in its trialsPapers from its trials146
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005416
GET https://conductscience.org/api/diseases/v1/MONDO_0005416/drugs?page=2